Oncology

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.

Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.

Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.

The investigators suggest that early detection and treatment of chronic kidney disease (CKD) in childhood cancer survivors may decrease late complications and mortality.

This segment takes a deeper dive into toxicity management—focusing not just on what to monitor, but how institutions are putting these protocols into action in real-world clinical settings.

Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.

Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.

Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).

The process teaches resilience, adaptability, and self-awareness.

APOBEC3 mutagenesis emerges as a key factor in breast cancer treatment resistance, offering new avenues for targeted therapies and predictive biomarkers.

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

The report highlights the expanding role of pharmacists in navigating regulatory, financial, logistical, and clinical complexities to ensure safe, equitable, and effective delivery of cell and gene therapies amid a rapidly growing and evolving treatment landscape.

The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.

In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration.

Studies suggest that prolonged activation of MUC1-C encourages disease progression.

The combination demonstrated improved efficacy compared with ruxolitinib as a monotherapy.

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

Pharmacists compare real-world practice data with clinical trial results and discuss supportive care options for patients.

A study reveals sasanlimab enhances event-free survival in high-risk bladder cancer patients, offering new hope against disease recurrence.

Pharmacists should continue to emphasize the vaccine’s effectiveness in preventing cancer and be prepared to address patient safety concerns.

Naxitamab-gqgk has been added as a Category 2A recommendation in the updated National Comprehensive Cancer Network (NCCN) guidelines for high-risk neuroblastoma, reflecting growing consensus on its role in treating relapsed or refractory disease.

Cynthia Ryan, PharmD, BCPS, discusses practical, evidence-based strategies for pharmacists to identify, prevent, and manage dermatologic toxicities associated with cancer therapies, emphasizing interdisciplinary collaboration, patient education, and proactive supportive care to improve adherence and outcomes.

New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.

The regimen, which consists of durvalumab and Bacillus Calmette-Guerin, offers new hope to patients with high-risk non-muscle-invasive bladder cancer.

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.